everything possible / Shutterstock.com
14 April 2016Americas
Regeneron agrees CRISPR/Cas licensing deal
Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.
Americas
11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.
Editor's picks
Editor's picks
Americas
29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.
Americas
11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.
Americas
29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.
Americas
11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.